ArticleMolecular cell2019
Second Messenger cA
Article in Molecular cell, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Mass spectrometry based identification of AMP-O-Tris generated by Thermococcus onnurineus Cas10.FEBS open bio · 2026Article
- Structural mechanism of SAM-AMP and SAM-AMPNature communications · 2026Article
- Article
- Article
- Review
- Nucleic acid recognition during prokaryotic immunity.Molecular cell · 2025Review
- Mechanistic determinants and dynamics of cA6 synthesis in type III CRISPR-Cas effector complexes.Nucleic acids research · 2025Article
- Nucleotide Immune Signaling in CBASS, Pycsar, Thoeris, and CRISPR Antiphage Defense.Annual review of microbiology · 2024Review
- The SAVED domain of the type III CRISPR protease CalpL is a ring nuclease.Nucleic acids research · 2024Article
- Molecular basis for cA6 synthesis by a type III-A CRISPR-Cas enzyme and its conversion to cA4 production.Nucleic acids research · 2024Article
- RNA targeting and cleavage by the type III-Dv CRISPR effector complex.Nature communications · 2024Article
- Current Updates of CRISPR/Cas System and Anti-CRISPR Proteins: Innovative Applications to Improve the Genome Editing Strategies.International journal of nanomedicine · 2024Review
- Arabinose- and xylose-modified analogs of 2',3'-cGAMP act as STING agonists.Cell chemical biology · 2023Article
- Article
- Functional and Phylogenetic Diversity of Cas10 Proteins.The CRISPR journal · 2023Article
- Bacterial origins of cyclic nucleotide-activated antiviral immune signaling.Molecular cell · 2022Review
- Type III-A CRISPR systems as a versatile gene knockdown technology.RNA (New York, N.Y.) · 2022Article
- Structural and biochemical characterization of in vivo assembled Lactococcus lactis CRISPR-Csm complex.Communications biology · 2022Article
- Enzymatic properties of CARF-domain proteins inFrontiers in microbiology · 2022Article
- Structure-based functional mechanisms and biotechnology applications of anti-CRISPR proteins.Nature reviews. Molecular cell biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Target RNA binding to crRNA-bound type III-A CRISPR-Cas multi-subunit Csm surveillance complexes activates cyclic-oligoadenylate (cA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.